I don't agree with the belief that LymPro was so c
Post# of 30070
Posted On: 06/03/2014 9:14:02 PM
I don't agree with the belief that LymPro was so cheap because there is no demand for the test. From statements made by Gerald, Dr. Lowe, and Dr. Simon, there are indications of significant demand for the test in both AD research and medical practice.
As for the real reasons why Amarantus was able to acquire LymPro so cheaply, the most complete discussion was given by Gerald himself in response to a question by Jason Napadano in the April 2013 investor conference call. There was up-front cash and shares, there is a milestone payment of $1MM, and there are 9% royalties going to MemoryDX upon commercialization. The acquisition is structured so Amarantus funds the commercialization and MemoryDX receives a percentage of the profits. In that regard, it's not as "cheap" as it seems. This is a significant amount of money going to MemoryDX if actual demand for the test reaches revenue estimates.
Here's a link to that discussion. It answers a lot of questions and dispels some false assumptions.
LymPro Acquisition
This post is a duplicate of my earlier IHub post. It is part of the larger 2013 Conference Call audio file from my preceding post.
As for the real reasons why Amarantus was able to acquire LymPro so cheaply, the most complete discussion was given by Gerald himself in response to a question by Jason Napadano in the April 2013 investor conference call. There was up-front cash and shares, there is a milestone payment of $1MM, and there are 9% royalties going to MemoryDX upon commercialization. The acquisition is structured so Amarantus funds the commercialization and MemoryDX receives a percentage of the profits. In that regard, it's not as "cheap" as it seems. This is a significant amount of money going to MemoryDX if actual demand for the test reaches revenue estimates.
Here's a link to that discussion. It answers a lot of questions and dispels some false assumptions.
LymPro Acquisition
This post is a duplicate of my earlier IHub post. It is part of the larger 2013 Conference Call audio file from my preceding post.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
The truth is incontrovertible. Malice may attack it, ignorance may deride it, or a narcissistic board moderator may delete it because it doesn't support his disjointed thinking, but in the end, there it is.
– Windbag Duckbill
– Windbag Duckbill